BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31097112)

  • 1. Low-grade Serous Neoplasia of the Female Genital Tract.
    Folkins AK; Longacre TA
    Surg Pathol Clin; 2019 Jun; 12(2):481-513. PubMed ID: 31097112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytopathology of serous neoplasia of the ovary and the peritoneum: differential diagnosis from mesothelial proliferations.
    Pisharodi LR; Bedrossian CW
    Diagn Cytopathol; 1996 Nov; 15(4):292-5. PubMed ID: 8982583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas: A Population-based Clinicopathologic Study of 942 Cases.
    Vang R; Hannibal CG; Junge J; Frederiksen K; Kjaer SK; Kurman RJ
    Am J Surg Pathol; 2017 Jun; 41(6):725-737. PubMed ID: 28248817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma.
    Chui MH; Xing D; Zeppernick F; Wang ZQ; Hannibal CG; Frederiksen K; Kjaer SK; Cope L; Kurman RJ; Shih IM; Wang TL; Vang R
    Am J Surg Pathol; 2019 Nov; 43(11):1462-1472. PubMed ID: 31343420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-grade serous tumors of ovary.
    Bell DA
    Int J Gynecol Pathol; 2014 Jul; 33(4):348-56. PubMed ID: 24901394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MORPHOPHENOTYPIC CHARACTERISTICS OF OVARIAN SEROUS BORDERLINE TUMORS.
    Munjishvili V; Barabadze E; Musashvili T; Gachechiladze M; Burkadze G
    Georgian Med News; 2019 May; (290):20-25. PubMed ID: 31322508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion.
    McKenney JK; Balzer BL; Longacre TA
    Am J Surg Pathol; 2006 Oct; 30(10):1209-21. PubMed ID: 17001150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progressive loss of selenium-binding protein 1 expression correlates with increasing epithelial proliferation and papillary complexity in ovarian serous borderline tumor and low-grade serous carcinoma.
    Zhang C; Wang YE; Zhang P; Liu F; Sung CJ; Steinhoff MM; Quddus MR; Lawrence WD
    Hum Pathol; 2010 Feb; 41(2):255-61. PubMed ID: 19896693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Well-differentiated serous neoplasms of the ovary.
    Longacre TA; Kempson RL; Hendrickson MR
    Pathology (Phila); 1993; 1(2):255-306. PubMed ID: 9420921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency of serous tubal intraepithelial carcinoma in various gynecologic malignancies: a study of 300 consecutive cases.
    Tang S; Onuma K; Deb P; Wang E; Lytwyn A; Sur M; Daya D
    Int J Gynecol Pathol; 2012 Mar; 31(2):103-10. PubMed ID: 22317864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ovarian high-grade serous carcinoma with a noninvasive growth pattern simulating a serous borderline tumor.
    Imamura H; Ohishi Y; Aman M; Shida K; Shinozaki T; Yasutake N; Sonoda K; Kato K; Oda Y
    Hum Pathol; 2015 Oct; 46(10):1455-63. PubMed ID: 26232113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noninvasive and invasive micropapillary (low-grade) serous carcinoma of the ovary: a clinicopathologic analysis of 135 cases.
    Smith Sehdev AE; Sehdev PS; Kurman RJ
    Am J Surg Pathol; 2003 Jun; 27(6):725-36. PubMed ID: 12766576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological significance of DEK overexpression in serous ovarian tumors.
    Han S; Xuan Y; Liu S; Zhang M; Jin D; Jin R; Lin Z
    Pathol Int; 2009 Jul; 59(7):443-7. PubMed ID: 19563407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nicotinamide N-methyltransferase overexpression may be associated with poor prognosis in ovarian cancer.
    Harmankaya İ; Akar S; Uğraş S; Güler AH; Ezveci H; Aydoğdu M; Çelik Ç
    J Obstet Gynaecol; 2021 Feb; 41(2):248-253. PubMed ID: 32285726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular subtypes of serous borderline ovarian tumor show distinct expression patterns of benign tumor and malignant tumor-associated signatures.
    Curry EW; Stronach EA; Rama NR; Wang YY; Gabra H; El-Bahrawy MA
    Mod Pathol; 2014 Mar; 27(3):433-42. PubMed ID: 23948749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoimplants in serous borderline tumors of the ovary: a clinicopathologic study of 30 cases of a process to be distinguished from serous adenocarcinoma.
    Rollins SE; Young RH; Bell DA
    Am J Surg Pathol; 2006 Apr; 30(4):457-62. PubMed ID: 16625091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fallopian tube precursors of ovarian low- and high-grade serous neoplasms.
    Vang R; Shih IeM; Kurman RJ
    Histopathology; 2013 Jan; 62(1):44-58. PubMed ID: 23240669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-grade ovarian serous neoplasms (low-grade serous carcinoma and serous borderline tumor) associated with high-grade serous carcinoma or undifferentiated carcinoma: report of a series of cases of an unusual phenomenon.
    Boyd C; McCluggage WG
    Am J Surg Pathol; 2012 Mar; 36(3):368-75. PubMed ID: 22082603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell polarity reversal in ovarian low-grade serous carcinomas and micropapillary serous borderline tumours: immunohistochemical observations.
    Hui Y; Ou JJ; Sung CJ; Lawrence WD; Quddus MR
    Histopathology; 2016 Nov; 69(5):892-894. PubMed ID: 27271798
    [No Abstract]   [Full Text] [Related]  

  • 20. Nanog is highly expressed in ovarian serous cystadenocarcinoma and correlated with clinical stage and pathological grade.
    Pan Y; Jiao J; Zhou C; Cheng Q; Hu Y; Chen H
    Pathobiology; 2010; 77(6):283-8. PubMed ID: 21266826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.